Clinical trials: Ascites
Malignant Ascites, Cancer
A Study of M701 (EpCAM and CD3) in Malignant Ascites
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
- Trial name
- NCT04501744
- Testing
- Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Cirrhosis, Liver, Refractory Ascites
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
This is a single centre, prospective, uncontrolled study to include 12 consecutive patients with cirrhosis of the liver and recurrent or refractory ascites.
- Trial name
- NCT01438970
- Testing
- ALFApump system
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Sequana Medical N.V.
Cirrhosis, Liver, Liver Fibrosis
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2).
- Conditions
- Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
- Trial name
- NCT05490888
- Testing
- PHIN-214 Subcutaneous injection
- Where
- 9 sites in United States
- Volunteers
- 74 people
- Sponsor
- PharmaIN
Cirrhosis, Ascites
A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites
The study is a multi-center, prospective, open label, uncontrolled feasibility study enrolling 30 patients with refractory or recurrent ascites and cirrhosis at up to 6 sites.
- Trial name
- MOSAIC (NCT02400164)
- Testing
- alfapump system
- Where
- 6 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Sequana Medical N.V.
Cancer, Neoplasms
CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
This is a randomized phase IIIb study investigating the treatment of malignant ascites due to epithelial cancer (carcinomas) with the trifunctional antibody catumaxomab.
- Conditions
- Cancer, Neoplasms, Carcinoma, Malignant Ascites
- Trial name
- CASIMAS (NCT00822809)
- Testing
- Catumaxomab, Prednisolone
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 230 people
- Sponsor
- Neovii Biotech
Malignant Ascites
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
A Randomized, Controlled, Multi-Center Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody (M701) for Intraperitoneal Injection to…
- Trial name
- NCT06432296
- Testing
- M701, paracentesis
- Where
- 2 sites in China
- Volunteers
- 312 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Cirrhotic Ascites
Phase II/III of Recombinant Human Serum Albumin
This is a randomized, double-blind, position-controlled, parallel group phase II/III clinical study of recombinant human serum albumin (rHSA) in cirrhotic ascites patients.
- Trial name
- NCT05858853
- Testing
- Recombinant Human Serum Albumin, Human serum albumin
- Where
- 25 sites in China
- Volunteers
- 92 people
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Acute-On-Chronic Liver Failure, Ascites
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and…
- Trial name
- NCT05900050
- Testing
- VS-01 on top of SOC, SOC (Control Group)
- Where
- 26 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Genfit
Hyponatremia and Extracellular Fluid in Cirrhotic
Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites
This study is to evaluate the efficacy of a 2-week course of tolvaptan in improving serum sodium and the excretion of extracellular fluid in liver cirrhotic patients with ascites and hyponatremia
- Trial name
- ECF (NCT01552590)
- Testing
- Tolvaptan
- Where
- 3 sites in South Korea
- Volunteers
- 74 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Cirrhotic Ascites
A Phase II Study of OsrHSA in Patients With Decompensated Cirrhotic Ascites
The study is designed to study the efficacy of IV OsrHSA or positive control HSA (10 g and 20 g IV everyday) for 14 days. After a screening period of up to 14 days, the eligible subjects will be randomized in a 4:1 ratio to…
- Trial name
- NCT04835480
- Testing
- OrsHSA, HSA
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Healthgen Biotechnology Corp.
Hypoalbuminemia in Cirrhotic Ascites
A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection in Healthy Trial Participants and Cirrhotic Trial Participants With Ascites and Hypoalbuminemia
This trial is conducted in China. This study plans to include 3 parts,Part A, a single ascending dose (SAD) study in healthy trial participants; Part B, a multiple dose (MD) study in healthy trial participants; and Part C, a…
- Trial name
- NCT07851688
- Testing
- Human Serum Albumin(HSA), GLR1075 Injection
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Ascites, Liver Cirrhosis
Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)
Primary:To evaluate the efficacy of satavaptan on top of conventional treatment in the treatment of clinically evident ascites in participants with cirrhosis of the liver.
- Trial name
- CATS (NCT00358878)
- Testing
- Satavaptan
- Where
- 21 sites in United States, Argentina and 19 more
- Volunteers
- 463 people
- Sponsor
- Sanofi
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Hepatorenal Syndrome
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.
- Trial name
- NCT01143246
- Testing
- Terlipressin
- Where
- 73 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Mallinckrodt
Ascites, Liver Cirrhosis
Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary: To evaluate the efficacy of satavaptan in the absence of concomitant diuretic drugs in reducing the recurrence of ascites.
- Trial name
- SPARe-2 (NCT00366795)
- Testing
- Satavaptan
- Where
- 21 sites in United States, Argentina and 19 more
- Volunteers
- 241 people
- Sponsor
- Sanofi
Hepatic Ascites
Recombinant Human Serum Albumin in Healthy Subjects
This trial adopts a single-center, randomized, double-blind, dose-escalation, placebo-controlled design to evaluate the safety, tolerability, pharmacokinetics, and efficacy of a single administration of recombinant human serum…
- Trial name
- NCT05179265
- Testing
- recombinant human serum albumin, Human serum albumin
- Where
- 2 sites in China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company